Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jamie Robyn

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Leukemia Research|March 15, 2006
Imatinib-responsive hypereosinophilic syndromeJamie Robyn
Advances in Immunology|May 10, 2006
Systemic mastocytosisJamie Robyn, Dean D Metcalfe
Immunology and Allergy Clinics of North America|August 26, 2006
Treatment of systemic mastocytosisTodd M Wilson, Dean D Metcalfe, Jamie Robyn
Leukemia & Lymphoma|December 29, 2004
Imatinib-responsive hypereosinophilia in a patient with B cell ALLJamie Robyn, Pierre Noel, Iwona Wlodarska, et al.
Blood|September 25, 2003
Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndromeAmy D Klion, Jamie Robyn, Cem Akin, et al.
British Journal of Haematology|January 18, 2006
Multilineage involvement of the fusion gene in patients with FIP1L1/PDGFRA-positive hypereosinophilic syndromeJamie Robyn, Steven Lemery, J Philip McCoy, et al.
Haematologica|December 8, 2010
Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosisTodd M Wilson, Irina Maric, Olga Simakova, et al.
Blood|August 15, 2002
HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndromeYogen Saunthararajah, Ryotaro Nakamura, Jun-Mo Nam, et al.
Haematologica|January 2, 2008
Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusionIdoya Lahortiga, Cem Akin, Jan Cools, et al.
Blood|August 22, 2007
Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosingAmy D Klion, Jamie Robyn, Irina Maric, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Leukemia Research|March 15, 2006
Imatinib-responsive hypereosinophilic syndromeJamie Robyn
Advances in Immunology|May 10, 2006
Systemic mastocytosisJamie Robyn, Dean D Metcalfe
Immunology and Allergy Clinics of North America|August 26, 2006
Treatment of systemic mastocytosisTodd M Wilson, Dean D Metcalfe, Jamie Robyn
Leukemia & Lymphoma|December 29, 2004
Imatinib-responsive hypereosinophilia in a patient with B cell ALLJamie Robyn, Pierre Noel, Iwona Wlodarska, et al.
Blood|September 25, 2003
Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndromeAmy D Klion, Jamie Robyn, Cem Akin, et al.
British Journal of Haematology|January 18, 2006
Multilineage involvement of the fusion gene in patients with FIP1L1/PDGFRA-positive hypereosinophilic syndromeJamie Robyn, Steven Lemery, J Philip McCoy, et al.
Haematologica|December 8, 2010
Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosisTodd M Wilson, Irina Maric, Olga Simakova, et al.
Blood|August 15, 2002
HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndromeYogen Saunthararajah, Ryotaro Nakamura, Jun-Mo Nam, et al.
Haematologica|January 2, 2008
Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusionIdoya Lahortiga, Cem Akin, Jan Cools, et al.
Blood|August 22, 2007
Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosingAmy D Klion, Jamie Robyn, Irina Maric, et al.
Pageof 2